p16 expression and its correlation with the clinical pathological characteristics of patients with cervical cancer: a
Le Chong1, Zuowei Zou2, Luhua Xia3
1Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Department of Ultrasonography, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, Xinjiang, China.
Objectives:
Overexpression of p16 has been documented in a variety of human tumours. Nonetheless, the association between p16 overexpression and the clinicopathological characteristics of patients with cervical cancer remains a subject of debate. This meta-analysis sought to systematically assess the relationship between p16 expression and the clinicopathological features of patients with cervical cancer.
Design:
Systematic review and meta-analysis.
Data Sources:
The PubMed, Embase, Cochrane Library (Central), Web of Science (SCI Expanded), and Chinese databases (CNKI, VIP, Wanfang and CBM) were searched through 1 March 2024.
Eligibility Criteria For Selecting Studies:
Case‒control studies examining the association between p16 expression and cervical cancer were analysed to evaluate whether p16 expression was correlated with the clinicopathological characteristics of patients with cervical cancer.
Data Extraction And Synthesis:
Two independent reviewers employed standardised methods to search, screen and code the included studies. The risk of bias was evaluated using the Cochrane Collaboration tools and the Newcastle-Ottawa Scale. Statistical analyses and data processing were conducted using Review Manager V.5.4, which included heterogeneity tests and sensitivity analyses. Additionally, STATA V.16.0 was used for further sensitivity analyses of the included studies, and publication bias was assessed using Begg's test.
Conclusions:
The p16 protein is strongly associated with the onset and progression of cervical cancer and serves as a valuable biomarker for its early detection and diagnosis.
Prospero Registration Number:
CRD42024546241.
